Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in IBO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $716K | +1503.9% | 1.107% | 0.00% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 708K | $425K | — | 0.657% | 0.00% |
| 3 | STATE STREET CORP | 608K | $365K | +5053.0% | 0.564% | 0.00% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 585K | $351K | — | 0.543% | 0.00% |
| 5 | BlackRock, Inc. | 260K | $156K | 0.0% | 0.241% | 0.00% |
| 6 | NORTHERN TRUST CORP | 244K | $146K | +2285.8% | 0.226% | 0.00% |
| 7 | TWO SIGMA INVESTMENTS, LP | 37K | $22K | -6.0% | 0.035% | 0.00% |
| 8 | UBS Group AG | 32K | $19K | +1394.6% | 0.030% | 0.00% |
| 9 | Vanguard Global Advisers, LLC | 32K | $19K | — | 0.030% | 0.00% |
| 10 | Mason & Associates Inc | 10K | $6K | 0.0% | 0.009% | 0.00% |
| 11 | MORGAN STANLEY | 9K | $6K | +0.1% | 0.009% | 0.00% |
| 12 | Global Trust Asset Management, LLC | 2K | $1K | — | 0.002% | 0.00% |
| 13 | CITIGROUP INC | 353 | $212 | +35200.0% | 0.000% | 0.00% |
| 14 | FMR LLC | 290 | $174 | — | 0.000% | 0.00% |
| 15 | WELLS FARGO & COMPANY/MN | 224 | $134 | 0.0% | 0.000% | 0.00% |
| 16 | Newbridge Financial Services Group, Inc. | 86 | $52 | 0.0% | 0.000% | 0.00% |
| 17 | CWM, LLC | 28 | $17 | 0.0% | 0.000% | 0.00% |
| 18 | Burk Holdings LLC | 27 | $16 | — | 0.000% | 0.00% |
| 19 | DANSKE BANK A/S | 3 | $2 | 0.0% | 0.000% | 0.00% |
| 20 | Center for Financial Planning, Inc. | 0 | $1 | — | 0.000% | 0.00% |
| 21 | ROYAL BANK OF CANADA | 32 | $0 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in IBO — a direct measure of their conviction.
Filings activity in IBO during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new IBO position in Q1 2026
Institutions that fully closed their IBO position in Q1 2026
7 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 21 | 13% | 3.54% | +2.40 pp | $2M | +210% |
| Q4 2025 | 24 | +14% | 1.14% | +0.57 pp | $1M | +101% |
| Q3 2025 | 21 | +11% | 0.57% | +0.10 pp | $0M | +20% |
| Q2 2025 | 19 | +19% | 0.47% | +0.08 pp | $0M | +22% |
| Q1 2025 | 16 | +60% | 0.39% | +0.30 pp | $0M | +321% |
| Q4 2024 | 10 | +11% | 0.09% | +0.04 pp | $0M | +81% |
| Q3 2024 | 9 | — | 0.05% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying IBO stock.
Based on Q1 2026 13F filings, institutional ownership of Impact BioMedical Inc. stands at 3.5%, held across 21 reporting institutions.
GEODE CAPITAL MANAGEMENT, LLC is the largest reported institutional holder of IBO, with approximately 1,192,925 shares worth $0.00B as of Q1 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of IBO, including TWO SIGMA INVESTMENTS, LP.
Our composite Smart Money Score for IBO is 52 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
7 institutions opened new positions in IBO during Q1 2026, while 10 fully exited. 11 added to existing positions and 0 trimmed.
IBO institutional ownership rose by 2.40 percentage points quarter-over-quarter, with a net change of -3 holders.
The top 10 institutions account for 99.7% of all reported 13F value in IBO, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Impact BioMedical Inc. (IBO) Institutional Ownership